Jenifer Bova

Dynamic Clinical Research Coordinator with extensive experience at the University of Arizona, excelling in project management and regulatory compliance. Proven track record in ensuring timely deliverables and enhancing quality assurance processes. Skilled in clinical documentation and adept at fostering strong vendor relationships, driving successful clinical trials and maintaining high standards of safety and accuracy.

• Nursing Assistant Certification(CNA), Pima Community College, 2018.
• CITI Health Information Privacy, Blood Bourne Pathogens, and Security HIPAA.
• First aid CPR
• IATA

• Harvey, E. M., Ramesh, D., Marshall, M. S., Martin, J. A., McGrath, E. R., Yescas, S., & Miller, J. M. (2024). Parent strategies for improving compliance with eyeglass wear in young children. Optometry and vision science, 101(4), 187–194.
• Marshall Gonzales MS, Ramesh D, Martin JA, Harvey EM. Parents of young children with eyeglasses: Experiences, challenges, and successes. Presented at the 56th Annual Communicating Nursing Research Conference, April 19-22, 2023, Tucson, AZ.
• Twelker JD, Arthur AA, Bhakta R, Davis AL, Dennis LK, Enriquez SG, Gerhart K, Hsu CH, Marshall S, Martin J, McGrath E, Miller JM, Ramesh R, Harvey EM. Comparing the Test Validity of the Spot Vision Screener using the 2013 and 2021 AAPOS Guidelines for Astigmatism. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5226.
• Twelker JD, Arthur AA, Bhakta R, Davis AL, Dennis LK, Enriquez SG, Gerhart K, Hsu CH, Marshall S, Martin J, McGrath E, Miller JM, Ramesh R, Harvey EM. Pediatric Vision Study Recruitment During and After the COVID-19 Pandemic. Presented at American Academy of Optometry Annual Meeting, October 2023, New Orleans, LA.
• Twelker JD, Arthur AA, Davis AL, Dennis LK, Enriquez SG, Gerhart K, Hsu CH, Marshall S, Martin J, McGrath E, Miller JM, Ramesh R, Harvey EM. Agreement between the Welch Allyn Spot Vision Screener and Cycloplegic Retinoscopy in Toddlers. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1403
• Miller JM, Harvey EM, Martin JA. Wearable sensor temperature data logger response rates when applied to spectacles for measurement of spectacle wear time. Presented at Annual Meeting of the American Ophthalmological Society, May, 2024, La Jolla, CA.s

• SPEC- Specatacle Prescribing in Early Childhood, University of Arizona Department of Ophthalmology and Vision Science, 11/2021, Current, A comparison of developmental outcomes for young children (12 to 35 months of age) with astigmatism meeting American Academy of Ophthalmology spectacle prescribing guidelines and who are prescribed and provided spectacles for either Full-Time wear (encouraged and reinforced) or Ad Lib wear (wear dependent on child acceptance).
• Regenxbio RGX-314-2104 Atmosphere, 07/2021, 11/2021, A randomized, partially masked, Controlled, Phase 2b/3 Clinical study to evaluate the efficacy and safety of RGX-314 Gene therapy in Participants with nAMD.
• Novartis Condor RTH258, 05/2021, 11/2021, A 96-week, two-arm, Randomized, Single-Masked, Multi-center, phase III study assessing the efficacy and safety of brolucizumab 6mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)
• Adverum biotechnologies ADVM-022-08, 05/2021, 11/2021, A multi-center, randomized, double-masked, active controlled study of ADVM-022(AAV.7m8-alfibercept) in Neovascular (wet_ Age- related Macular Degeneration.
• Genentech Gallego GR40973, 01/2021, 11/2021, A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to assess the safety, tolerability, and Efficacy of Intravitreal injections of FHTR2163 in Patients with Geographic atrophy secondary to Age-related Macular degeneration
• Alimera Sciences 01-20-005, 01/2021, 11/2021, A phase IV randomized, Masked, Controlled study of intravitreal Iluvien implant as baseline therapy in patients with early Diabetic Macular Edema.
• Genentech Rhone-x GR41987, 11/2020, 11/2021, A multicenter, Open-Label, extension study to evaluate the long-term safety and tolerability of Faricimab in patients with diabetic Macular Edema.
• Genentech Comino GR41986, 04/2021, 11/2021, A phase III, Multicenter, Randomized, Double Masked, Active Comparator-Controlled study to evaluate the efficacy and safety of faricimab in patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
• Novartis CRTH258B2305 Kingfisher, 01/2020, 11/2021, A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III study assessing the efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adults Patients with Visual Impairment due to Diabetic Macular Edema.
• Chengdu Kanghong Biotechnology Co., Ltd PANDA, 01/2020, 11/2021, A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration.
• Outlook Therapeutics ONS-5010-002, 06/2019, 11/2021, A Clinical Effectiveness, Multicenter, Randomized, Double-masked, Controlled Study of the Efficacy and Safety of ONS-5010 in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).
• Aura AU-001-101, 02/2019, 11/2021, A Phase 1b/2 open-label, ascending single and repeat dose clinical trial designed to evaluate the safety and efficacy of Light-activated AU-011 for the treatment of subjects with small primary choroidal melanoma.
• Roche Tenaya-GR40306, 02/2019, 11/2021, A phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration.
• Roche Yosemite GR40349, 07/2018, 11/2021, A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (YOSEMITE